Related Experiment Videos
Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil
D L Paterson1, N Singh, A Panebianco
1Infectious Disease Section, Veterans Affairs Medical Center, Pittsburgh, Pennsylvania 15240, USA.
Background:
Mycophenolate mofetil (MMF) is a new immunosuppressive agent that is gaining widespread use in solid organ transplantation recipients. A comprehensive assessment of infectious complications after its use after liver transplantation has never been assessed.
Methods:
Bacterial, fungal, and viral infections occurring after transplantation were compared for a cohort of consecutive liver transplant recipients who received MMF (because of suspected tacrolimus-related nephrotoxicity or neurotoxicity) and a cohort who did not receive the drug. All patients received a tacrolimus-based primary immunosuppressive protocol.
Results:
Biopsy-proven acute rejection episodes within the first 6 months after transplant occurred in 6% of MMF-treated patients but in 30% of those who did not receive MMF (P=0.07). No significant differences were found in occurrence of cytomegalovirus infection or disease, Pneumocystis carinii, Aspergillus, or other fungal infection and hepatitis C virus recurrence between MMF-treated and untreated patients. Bacterial infections were more common in MMF-treated patients, but this cohort had a prolonged intensive care unit stay compared with patients who did not receive MMF. None of the MMF-treated patients with bacterial infection had leukopenia.
Conclusions:
MMF use does not appear to be associated with an significantly increased risk of infection occurring after liver transplantation and is associated with fewer episodes of acute rejection.
Insights
Mycophenolate mofetil (MMF) use in liver transplant recipients did not significantly increase infection risk. MMF was associated with fewer acute rejection episodes, suggesting a favorable safety profile for this immunosuppressive agent.
Area of Science:
- Immunosuppression in transplantation
- Transplant infectious complications
- Gastroenterology and Hepatology
Background:
- Mycophenolate mofetil (MMF) is an emerging immunosuppressant used in organ transplantation.
- Comprehensive data on infectious complications following MMF in liver transplant recipients is limited.
Purpose of the Study:
- To assess infectious complications in liver transplant patients receiving MMF.
- To compare infection rates between MMF-treated and untreated cohorts.
Main Methods:
- Retrospective cohort study comparing liver transplant recipients who received MMF versus those who did not.
- Both groups followed a tacrolimus-based immunosuppressive protocol.
- Infections (bacterial, fungal, viral) were monitored post-transplant.
Main Results:
- No significant difference in cytomegalovirus, fungal, or hepatitis C virus recurrence between groups.
- Bacterial infections were more frequent in MMF patients, but this was confounded by longer ICU stays.
- MMF-treated patients showed a trend towards fewer acute rejection episodes (6% vs. 30%).
Conclusions:
- MMF use in liver transplantation is not associated with a significantly increased risk of infection.
- MMF is linked to a reduction in acute rejection episodes post-liver transplant.